ClinicalTrials.gg
CompletedNCT01202097CAINAS SFUpdated Mar 31, 2025

A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma

A Phase 3 interventional study of Salmeterol/Fluticasone and Seretide in Asthma, sponsored by Eurofarma Laboratorios S.A.. Completed at 6 sites in Brazil. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-03-31.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
16th of 46
334 · median 128
Started
2011
the only one that year
Phase 3
6 of 46
none open now
Registered
34th of 46
by date
Lead sponsor
1 of 46
Eurofarma Laboratorios S.A.

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 16th largest by enrollment, is the only one that started in 2011, is one of 6 in phase 3, and was the 34th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.

Read the detailed description

The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.

Primary endpoint: Forced expiratory volume in 1 second (FEV1) at the final visit.

Secondary endpoints: Expiratory Flow Peak (EFP), symptoms score, FEV1 throughout the study, use of rescue medication, compliance with inhaler use, inhaler acceptance and preference, and frequency of the observed adverse events.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the ICF
  • ≥ 12 years old
  • Have a persistent asthma diagnosis, as per GINA classification,18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test (please see Appendix C) ≤ 3.0
  • Current use of inhaled (up to 1000 µg of beclomethasone dipropionate) whether combined or not with long-term β2-adrenergics and relief medication (salbutamol or equivalent)
  • Initial of at least 40% of the normal value expected
  • Blood cortisol evaluation within the normal limits.

Exclusion criteria

Exclusion Criteria:

  • Use of oral or parenteral within the last 3 previous months to the study
  • Hospitalization needed due to asthma within the last 3 previous months to the study
  • Active smokers, defined as the consumption of cigarettes, pipes, cigars or any other form of smoking in any amount within the last 3 months
  • Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological or psychiatric disease or chronic respiratory disease other than asthma
  • Recent (\<6 months) or expected participation during this study in other clinical trials involving drugs of any nature or in studies consisting of any - Intolerance or allergy to any component of the drugs evaluated in the study
  • Pregnant or lactating women
  • Chronic use of routine β-blockers, orally or intravenously, including ophthalmic solutions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
334 participants (actual)

Study arms

  • Experimental
    Salmeterol/Fluticasone

    Drug: Salmeterol/Fluticasone

  • Active comparator
    Seretide

    Drug: Seretide

Interventions

06

What researchers measure

Primary outcomes

  1. Forced expiratory volume in 1 second (FEV1) at the final visit.

Secondary outcomes

  1. Expiratory Flow Peak (EFP)

07

Study locations

6 sites
  • Hospital de Clinicas UFPR
    Curitiba, PR, Brazil
  • Centro de Referencia em Enfermidades Respiratoria e Alergica
    Salvador, BA, Brazil
  • Clinica de Alergia Martti Antila
    Sorocaba, SP, Brazil
  • Centro de Estudos de Pneumologia FMABC
    São Paulo, Brazil
  • IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada
    São Paulo, Brazil
  • Stelmach Pesquisa Clinica
    São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2010
First posted
Sep 15, 2010
Start
Aug 2011
CompletionActual
May 2012
Last update
Mar 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01202097
Responsible party
Sponsor
First posted
Sep 15, 2010
Start date
Aug 2011
Completion
May 2012
Last update
Mar 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion